Approach to seizure
approach to seizure classification diagnosis management
seizure classification algorithm approach
| Type | Subtypes | Key Features |
|---|---|---|
| Focal | Aware / Impaired awareness | Originates in one hemisphere; may or may not affect consciousness |
| Generalized | Motor / Non-motor (absence) | Involves both hemispheres from onset |
| Unknown onset | Motor / Non-motor | Onset not determined |
| Category | Examples |
|---|---|
| Vascular | Stroke, AVM, hypoxic-ischemic injury |
| Infectious | Meningitis, encephalitis, brain abscess, neurocysticercosis |
| Trauma | TBI, subdural hematoma |
| Autoimmune | Anti-NMDAR encephalitis, LGI1, CASPR2 |
| Metabolic | Hypo/hypernatremia, hypoglycemia, hypocalcemia, uremia, hepatic encephalopathy, hypomagnesemia |
| Idiopathic / Genetic | Genetic epilepsy syndromes |
| Neoplastic | Primary/metastatic brain tumors |
| Structural / Substance | Cortical dysplasia, alcohol withdrawal, drug toxicity |
| Test | Purpose |
|---|---|
| Blood glucose (fingerstick) | Rule out hypoglycemia immediately |
| BMP (electrolytes, Ca, Mg, BUN, Cr) | Metabolic causes |
| CBC | Infection |
| LFTs | Hepatic encephalopathy |
| Toxicology screen | Drug/alcohol |
| Prolactin (within 20 min post-ictal) | Elevated after GTC/focal seizures; not after pseudoseizures |
| Pregnancy test (females of reproductive age) | Eclampsia |
| AED levels (if on therapy) | Subtherapeutic levels |
| Phase | Time | Intervention |
|---|---|---|
| Phase 1 (0-5 min) | ABC, O₂, IV access, glucose, labs | Thiamine 100 mg IV before dextrose if alcoholic/malnourished |
| Phase 2 (5-20 min) | 1st line: Benzodiazepines | Lorazepam 0.1 mg/kg IV (max 4 mg/dose), repeat once; or midazolam 10 mg IM (if no IV) |
| Phase 3 (20-40 min) | 2nd line: IV AED | Levetiracetam 60 mg/kg IV, OR valproate 40 mg/kg IV, OR fosphenytoin 20 PE/kg IV |
| Phase 4 (>40 min) | Refractory SE | Propofol, midazolam infusion, or ketamine; ICU admission, intubation, continuous EEG |
| Seizure Type | First-Line AEDs |
|---|---|
| Focal (with/without secondary generalization) | Levetiracetam, lamotrigine, carbamazepine, lacosamide |
| Generalized tonic-clonic | Valproate, levetiracetam, lamotrigine |
| Absence | Ethosuximide (first-line), valproate, lamotrigine |
| Myoclonic | Valproate, levetiracetam, clonazepam |
| Juvenile myoclonic epilepsy | Valproate, levetiracetam (avoid carbamazepine — may worsen) |
| Condition | Distinguishing Feature |
|---|---|
| Syncope | Prodrome, brief tonic posturing, no post-ictal confusion, rapid recovery |
| PNES (Psychogenic non-epileptic seizures) | No EEG correlate, pelvic thrusting, eye closure, normal prolactin |
| TIA | Negative symptoms (weakness/numbness), not positive (jerking) |
| Migraine with aura | Slow march of symptoms over minutes |
| Hypoglycemia | Corrected with glucose, no EEG correlate |
| Breath-holding spells | Pediatric, triggered by crying/pain |
| REM sleep behavior disorder | During REM sleep, dream enactment |
| Situation | Key Points |
|---|---|
| Febrile seizures | Age 6 mo–5 yr; >15 min = complex; LP if <12 mo or meningeal signs |
| Eclampsia | Hypertension + proteinuria + seizure in pregnancy; MgSO₄ is treatment |
| Alcohol withdrawal | 6-48 hrs post cessation; benzodiazepines are treatment |
| Neonatal seizures | Subtle (eye deviation, lip smacking); phenobarbital first-line |
| Post-stroke seizures | Early (<2 wks) = provoked; late = unprovoked, consider AED |
Bottom line: The approach begins with distinguishing provoked vs. unprovoked seizure, classifying the seizure type (ILAE 2017), identifying the etiology, and managing acutely with benzos → IV AED → ICU if needed. Long-term AED selection is guided by seizure type, patient profile, and comorbidities.